What Did We Learn (and Did Not Learn) from the Pediatric Direct Oral Anticoagulant Trials, and How Might We Better Design Pediatric Anticoagulant Trials in the Future?

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2023 May 11

PMID 37168398

Authors

Marisol Betensky

Paul Monagle

Christoph Male

Neil A Goldenberg

Affiliations

Soon will be listed here.

Abstract

A State of the Art lecture titled "What the direct oral anticoagulants (DOACs) trials did and didn't tell us" was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. The use of DOACs in children is of particular interest as they exhibit several advantages over conventional anticoagulation agents most commonly used in pediatrics. To date, several DOAC pediatric investigational programs (PIPs) have been completed, and although they have provided some of the best quality of evidence in pediatric anticoagulation therapy, the data generated by these trials remain limited. Here, we review and summarize the currently available data provided by the DOAC PIPs, provide perspectives on what we have and have not learned from these trials, and how we might leverage this knowledge to optimize the design of future anticoagulant PIPs. Finally, we summarize relevant new data on this topic presented during the 2022 ISTH Congress.

Citing Articles

Systematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases.

Guan C, Guo L, Liang S Clin Appl Thromb Hemost. 2024; 30():10760296241271974.

PMID: 39099474 PMC: 11301724. DOI: 10.1177/10760296241271974.

References

Schoenfeld D, Zheng H, Finkelstein D . Bayesian design using adult data to augment pediatric trials. Clin Trials. 2009; 6(4):297-304. PMC: 3374646. DOI: 10.1177/1740774509339238. View

Jaffray J, Mahajerin A, Young G, Goldenberg N, Ji L, Sposto R . A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project. Thromb Res. 2017; 161:67-72. DOI: 10.1016/j.thromres.2017.11.019. View

Wawrzynska L, Tomkowski W, Przedlacki J, Hajduk B, Torbicki A . Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003; 33(2):64-7. DOI: 10.1159/000073848. View

Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V . Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost. 2013; 11(10):1850-4. DOI: 10.1111/jth.12372. View

Brandao L, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell L . Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2019; 135(7):491-504. PMC: 7019192. DOI: 10.1182/blood.2019000998. View

Monagle P, Cuello C, Augustine C, Bonduel M, Brandao L, Capman T . American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018; 2(22):3292-3316. PMC: 6258911. DOI: 10.1182/bloodadvances.2018024786. View

van Ommen C, Albisetti M, Bhatt M, Bonduel M, Branchford B, Chalmers E . International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost. 2021; 19(4):1123-1129. PMC: 8252713. DOI: 10.1111/jth.15260. View

Payne J . Aspects of anticoagulation in children. Br J Haematol. 2010; 150(3):259-77. DOI: 10.1111/j.1365-2141.2010.08225.x. View

Sochet A, Morrison J, Jaffray J, Godiwala N, Wilson H, Thornburg C . Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics. 2022; 150(1). DOI: 10.1542/peds.2022-056726. View

10.

Portman M, Jacobs J, Newburger J, Berger F, Grosso M, Duggal A . Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol. 2022; 80(24):2301-2310. DOI: 10.1016/j.jacc.2022.09.031. View

11.

Newall F, Johnston L, Ignjatovic V, Monagle P . Unfractionated heparin therapy in infants and children. Pediatrics. 2009; 123(3):e510-8. DOI: 10.1542/peds.2008-2052. View

12.

Faustino E, Shabanova V, Raffini L, Kandil S, Li S, Pinto M . Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial. Crit Care Med. 2020; 49(3):e235-e246. PMC: 7902342. DOI: 10.1097/CCM.0000000000004784. View

13.

Young G, Lensing A, Monagle P, Male C, Thelen K, Willmann S . Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020; 18(7):1672-1685. DOI: 10.1111/jth.14813. View

14.

Vinks A, Barrett J . Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. J Clin Pharmacol. 2021; 61 Suppl 1:S52-S59. DOI: 10.1002/jcph.1841. View

15.

Chiodelli P, Bugatti A, Urbinati C, Rusnati M . Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015; 20(4):6342-88. PMC: 6272510. DOI: 10.3390/molecules20046342. View

16.

Branstetter J, Kiskaddon A, King M, Coalter C, Grubbs K, Fly H . Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. Semin Thromb Hemost. 2021; 47(6):643-653. DOI: 10.1055/s-0041-1725944. View

17.

Halton J, Brandao L, Luciani M, Bomgaars L, Chalmers E, Mitchell L . Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2020; 8(1):e22-e33. DOI: 10.1016/S2352-3026(20)30368-9. View

18.

Goldenberg N, Tripputi M, Crowther M, Abshire T, DiMichele D, Manco-Johnson M . The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials. 2009; 31(1):131-3. DOI: 10.1016/j.cct.2009.11.006. View

19.

Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J . Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet. 2013; 53(1):89-102. PMC: 3889826. DOI: 10.1007/s40262-013-0090-5. View

20.

Male C, Lensing A, Palumbo J, Kumar R, Nurmeev I, Hege K . Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2019; 7(1):e18-e27. DOI: 10.1016/S2352-3026(19)30219-4. View